The Satchel

DENVER, CO / ACCESSWIRE / February 23, 2016 / American Cannabis Company, Inc. (OTCQB: AMMJ) (the “Company”), a full-service business-to-business consulting solutions provider, and seller of ancillary products to the cannabis industry, today announced it has received notice from the US patent office that the claims of its SatchelTM patent application have been deemed allowable and the application will now move on to issuance. The issue fee was paid to the patent office on February 18th 2016. Under normal circumstances, it takes about 5-6 weeks for the patent office to issue the patent, assign the patent number and print the patent certificate.

The SatchelTM is a child-resistant vessel that may be used by dispensaries to assemble orders and ensure the proper post sale handling of cannabis per each state’s legislation. American Cannabis Company’s SatchelTM has also been awarded an approval from the American Society for Testing and Materials (ASTM). The SatchelTM was granted approval after a mandatory two month review and testing process.

Corey Hollister, president and CEO, American Cannabis Company, commented: “The SatchelTM provides increased safety for patients against accidental ingestion by children and animals. As the medical cannabis markets continue to grow these types of responsible measures will be key to ensuring continued public safety. In addition to meeting this need the Satchel also provides operators with an additional branding vehicle for their customers.”

About American Cannabis Company, Inc.:

American Cannabis Company, Inc. offers end-to-end solutions to existing and aspiring participants in the cannabis industry. We utilize our industry expertise to provide business planning and market assessment services, assist state licensing procurement, create business infrastructure and operational best practices. Through our two vertically integrated businesses, American Cannabis Consulting and American Cultivator Company, a group purchasing organization, we support our clients from concept to creation to commercialization to on-going operations.

For more information, please visit:

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward- looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit


Steven Lico
Marketing Coordinator
[email protected]
(303) 974-4770